Does diabetes therapy influence the risk of cancer?

Coughlin SS et al (2004) Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 159:1160–1167 Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687 Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083 Larsson SC, Mantzoros CS, Wolk A (2007) Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121:856–862 Zendehdel K, Nyrén O, Östenson C-G, Adami H-O, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800 Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate and pancreas. Gastroenterology 132:2208–2225 Mulnier HE, Seaman HE, Raleigh VS, Soedamah-Muthu SS, Colhoun HM, Lawrenson RA (2006) Mortality in people with type 2 diabetes in the UK. Diabetic Med 23:516–521 Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304–1305 Bowker SL et al (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258 Currie CJ, Poole CD, Gale EAM (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia doi:10.1007/s00125-009-1440-6 Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M et al (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269–10273 Schimmack G, DeFronzo RA, Musi N (2006) AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 8:591–602 Sahra IB, Laurent K, Loubat A et al (2008) The antidiabetic drug metformin exerts an antitumour effect in vitro and in vivo through a decrease in cyclin D1 level. Oncogene 27:3576–3586 Pearce EL, Walsh MC, Cejas PJ et al (2009) Enhancing CD8 T cell memory by modulating fatty acid metabolism. Nature. doi:10.1038/nature08097 Yang Y-X, Hennessy S, Lewis JD (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127:1044–1050 Hsu IR, Kim SP, Kabir M, Bergman RN (2007) Metabolic syndrome, hyperinsulinemia, and cancer. Am J Clin Nutr 86:867S–871S Holly JMP, Perks CM (2008) Cancer as an endocrine problem. Best Pract Res Clin Endocrinol Metab 22:539–550 Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70 Samani AA, Yakar S, LeRoith D, Brodt P (2007) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47 Kim JJ, Accili D (2002) Signalling through IGF-1 and insulin receptors: where is the specificity? Growth Horm IGF Res 12:84–90 Frasca F, Pandini G, Scalia P et al (1999) Insulin receptor isoform A, a newly recognised, high affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 19:3278–3288 Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107:873–877 Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia doi:10.1007/s00125-009-1418-4 Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. doi:10.1007/s00125-009-1444-2 Colhoun HM, SDRN Epidemiology group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. doi:10.1007/s00125-009-1453-1 http://www.fda.gov/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm122978.htm, accessed 15 June 1009 Mathieu C, Gale EAM (2008) Inhaled insulin: gone with the wind? Diabetologia 51:1–5 Berger M (2000) Safety of insulin glargine. Lancet 356:2013 Ebeling P, Tuominen JA, Koivisto VA (1996) Insulin analogues and carcinoma of the breast. Diabetologia 39:124–125 Hansen BF, Danielsen GM, Drejer K et al (1996) Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 315:271–279 Slieker LJ, Brooke GS, DiMarchi RD et al (1997) Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 40:S54–S61 Jorgensen L, Dideriksen L, Drejer K (1992) Carcinogenic effect of the human insulin analogue B10Asp in female rats. Diabetologia 35(Suppl 1):A3 (Abstract) Kurtzhals P, Schäffer L, Sørensen A et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999–1005 Erbel S, Büchler MW, Reers C et al (2008) Proliferation of colo-357 pancreatic carcinoma cells and survival of patients with pancreatic carcinoma are not altered by insulin glargine. Diabetes Care 31:1105–1111 Weinstein D, Simon M, Yehezkel E, Laron Z, Werner H (2008) Insulin analogues display IGF-1-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 25:41–49 Shukla A, Grisouard J, Ehemann V, Hermani A, Enzmann H, Mayer D (2009) Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. Endocr Relat Cancer 16:429–441 Kuerzel GU, Shukla U, Scholtz HE et al (2003) Biotransformation of insulin glargine after subcutaneous injection in healthy subjects. Curr Med Res Opin 19:34–40 Agin A, Jeandidier N, Gasser F, Grucker D, Sapin R (2007) Glargine blood biotransformation: in vitro appraisal with human insulin immunoassay. Diabetes Metab 33:205–212 Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G (2002) Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxicol 21:171–179 http://www.drugs.com/pro/lantus.html, accessed 15 June 2009 Rosenstock J, Fonseca V, McGill JB et al (2009) Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. doi:10.1007/s00125-009-1415-7 Schneider MB, Matsuzaki H, Haorah J et al (2001) Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 120:1263–1270 Matveyenko AV, Dry S, Cox HI et al (2009) Beneficial endocrine but adverse exocrine effects of sitagliptin in the HIP rat model of type 2 diabetes, interactions with metformin. Diabetes. doi:10.2337/db09-0058 Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB (2001) Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631–636 Zib I, Raskin P (2006) Novel insulin analogues and its mitogenic potential. Diabetes Obes Metab 8:611–620 Shaw LC, Grant MB (2004) Insulin like growth factor-1 and insulin-like growth factor binding proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology. Rev Endocr Metab Disord 5:199–207 Black N (1996) Why we need observational studies. BMJ 312:1215–1218 Papanikolaou PN, Christidi GD, Ioannidis JP (2006) Comparision of evidence on harms of medical interventions in randomized and non-randomized studies. CMAJ 174:635–641 Holleman F, Gale EAM (2007) Nice insulins, pity about the evidence. Diabetologia 50:1783–1790 Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW et al (2007) Long-acting insulin analogues vs NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev issue 2:art. no. CD005613. doi:10.1002/14651858.CD005613.pub3. Nathan DM, Buse JM, Davidson MB et al (2009) Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52:17–30 Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H (2009) Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 180:385–397 Barone BB, Yeh H-C, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with pre-existing diabetes mellitus. A systematic review and meta-analysis. JAMA 300:2754–2764 Frayling TM, Colhoun H, Florez JC (2008) A genetic link between type 2 diabetes and prostate cancer. Diabetologia 51:1757–1760